Source comparison
PT-141 for HSDD: Comparison Table
The following table compares PT-141 for HSDD to other treatments for low sexual desire in premenopausal women, focusing on mechanism of action, dosing schedule, time to effect, and adverse event profile. | Treatment | Mechanism of Action | Dosing Schedule | Ti
This comparison does not assign a generated winner or score.
- The following table compares PT-141 for HSDD to other treatments for low sexual desire in premenopausal women, focusing on mechanism of action, dosing schedule, time to effect, and adverse event profile.
- | Treatment | Mechanism of Action | Dosing Schedule | Time to Effect | Common Adverse Events | FDA Approval Status | Professional Assessment ||—|—|—|—|—|—|| PT-141 (Bremelanotide) | Melanocortin receptor agonist (MC3R/MC4R) in hypothalamus | On-demand subcutaneous injection 45 min before activity | 1–6 hours (variable) | Nausea 40%, flushing 20%, transient BP increase | FDA-approved for HSDD (2019) | Best for patients seeking on-demand dosing without daily medication; nausea limits tolerability || Flibanserin (Addyi) | 5-HT1A agonist, 5-HT2A antagonist | Daily oral dosing (100 mg at bedtime) | 4–8 weeks of daily use | Dizziness 11%, somnolence 11%, nausea 10% | FDA-approved for HSDD (2015) | Requires daily adherence and weeks to take effect; contraindicated with alcohol || Testosterone (Off-Label) | Androgen receptor agonist | Daily transdermal gel or weekly injection | 2–4 weeks of daily/weekly dosing | Acne, hirsutism, voice deepening, lipid changes | Not FDA-approved for HSDD in pre